Passage Bio, Inc. filed a current report on Form 8-K on November 19, 2026, disclosing under Regulation FD that Remix Therapeutics, Inc. issued a press release announcing updated Phase 1 data from the ARIA Phase 1/2 clinical trial of REM-422 in adenoid cystic carcinoma patients.
Key Highlights
- Registrant: Passage Bio, Inc., listed on the Nasdaq Capital Market under NASDAQ:PASG
- Disclosure entity: Remix Therapeutics, Inc. issued the underlying press release, dated November 19, 2026
- Clinical program: Updated Phase 1 data from the ongoing ARIA Phase 1/2 clinical trial of REM-422, described as an oral MYB mRNA degrader
- Target indication: Patients with adenoid cystic carcinoma (ACC)
- Presentation venue: A late-breaking oral presentation at the 2026 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
- Filing signatory: Kathleen Borthwick, Chief Financial Officer, signed on behalf of Passage Bio, Inc.
Passage Bio Discloses Remix Therapeutics ARIA Trial Update Under Regulation FD
Passage Bio, Inc. (NASDAQ:PASG) filed a current report on Form 8-K dated November 19, 2026, under Item 7.01, Regulation FD Disclosure. According to the filing, Remix Therapeutics, Inc. issued a press release on that date announcing updated Phase 1 data from the ongoing ARIA Phase 1/2 clinical trial of REM-422. The filing describes REM-422 as "an oral MYB mRNA degrader" being studied in patients with adenoid cystic carcinoma (ACC).
The filing notes that the data were presented in a late-breaking oral presentation at the 2026 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. A copy of the Remix Therapeutics press release was attached as Exhibit 99.1 to the report. No specific efficacy figures, safety data, or numerical clinical results are reproduced within the body of the 8-K itself; those details are contained in the attached exhibit.
As stated in the filing, the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed to be 'filed' for purposes of Section 18 of the Exchange Act," and is not incorporated by reference into other filings except as expressly specified. Passage Bio described itself as a remote-only company, with no headquarters address, directing stockholder communications to P.O. Box 7, Hopewell, New Jersey 08525.
What Was Disclosed
Passage Bio filed an 8-K on November 19, 2026, to disclose under Regulation FD that Remix Therapeutics announced updated ARIA Phase 1/2 trial data for REM-422 in adenoid cystic carcinoma at the 2026 ENA Symposium. The press release was attached as Exhibit 99.1.




Please wait processing your request...